Hatfield, England (ots/PRNewswire) - FOR EU MEDIA ONLY: NOT FOR SWISS MEDIA Accelerated Review Demonstrates the Importance of Lenvatinib for This Therapeutic Area The European Medicines Agency (EMA) has approved Eisai's request for accelerated assessment of the investigational oral multiple receptor tyrosine kinase ...
Hatfield, England (ots/PRNewswire) - Zonegran(R) (zonisamide) has been approved by the Scottish Medicines Consortium (SMC) for the treatment of partial epilepsy in adolescents and children aged six years and above in Scotland.[1] This decision follows zonisamide's paediatric license extension approval by the ...
Hatfield, England (ots/PRNewswire) - Eisai announces today that Zebinix(R) (eslicarbazepine acetate), a novel anti-epilepsy treatment, has received full reimbursement from the Finnish Health Authorities. Once-daily eslicarbazepine acetate, is indicated as adjunctive therapy in adults with partial onset seizures, ...
Hatfield, England (ots/PRNewswire) - The investigational monoclonal antibody amatuximab (development code: MORAb-009), has today been granted orphan drug designation (ODD) for the treatment of malignant mesothelioma by the European Commission. Malignant mesothelioma is a rare form of cancer that affects an estimated ...
Hatfield, England (ots/PRNewswire) - Fycompa(R) (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), launches today in Spain. The new therapy is indicated for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 ...
Hatfield, England (ots/PRNewswire) - Halaven(R) (eribulin) has received reimbursement approval in the Czech Republic as a highly innovative drug for patients with metastatic breast cancer, effective from the 1 January 2014. Eribulin is the first, single-agent chemotherapy to demonstrate a prolonged overall survival ...
Hatfield, England (ots/PRNewswire) - Epilepsy treatment Fycompa(R)(perampanel) has today been approved for basic reimbursement in Finland. Perampanel is indicated as an adjunctive treatment for partial onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.[1] Perampanel is the first and only licensed ...
Hatfield, England (ots/PRNewswire) - Eisai announces today that it has expanded the marketing and supply agreement between its U.S. subsidiary Eisai Inc. and U.S-based Arena Pharmaceuticals Inc.'s Swiss subsidiary, Arena Pharmaceuticals GmbH, for the anti-obesity agent lorcaserin hydrochloride (lorcaserin) (U.S. ...
Hatfield, England (ots/PRNewswire) - First shipment to benefit more than 6 million people in 4 endemic countries Eisai announced today that it has begun the free supply of diethylcarbamazine citrate (DEC) 100 mg tablets produced at its Vizag Plant in India to the World Health Organization (WHO) in line with its ...
Hatfield, England (ots/PRNewswire) - New data on early real life experience show perampanel is effective and well tolerated in patients with difficult-to-treat partial epilepsy The antiepileptic drug (AED) Fycompa (perampanel), shows a clear therapeutic benefit in difficult-to-treat patients with partial epilepsy according to the investigators of two new analyses on ...
Hatfield, England (ots/PRNewswire) - Child friendly formulation will help treatment of orphan syndrome LGS a severe form of childhood epilepsy Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in France. The new formulation of the orphan ...
Frankfurt, Germany And Hatfield, England (ots/PRNewswire) - The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system in Germany, today announced that it considers the additional benefit of Fycompa(R) (perampanel) unproven when compared to two other treatments as ...
Hatfield, England (ots/PRNewswire) - Eisai today launches Fycompa(R) (perampanel) in Norway as a treatment for partial-onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.[1] Perampanel is the first in an entirely new class of treatment for uncontrolled partial epilepsy, the most common form of the ...
Hatfield, England (ots/PRNewswire) - Child friendly formulation set to aid administration for the treatment of Lennox-Gastaut syndrome Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in Spain. As many patients who receive the orphan ...
Hatfield, England (ots/PRNewswire) - Eisai's new investigational molecule discovered and developed collaboratively in the UK and Japan Eisai in Europe today releases the first clinical data for E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor, presented during oral sessions at the ...
Hatfield, England (ots/PRNewswire) - Metastatic breast cancer treatment Halaven(R) (eribulin) provides a statistically significant overall survival benefit for women with the disease Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from ...
Hatfield, England (ots/PRNewswire) - Reimbursement granted for Halaven(R) (eribulin) for women with locally advanced or metastatic breast cancer Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has today received reimbursement approval from the French health authorities. Prior ...
Hatfield, England (ots/PRNewswire) - Eisai Europe Limited today announces preliminary results from a recently completed Phase III study (Study 301) comparing Halaven(R) (eribulin) and Xeloda(R) (capecitabine). The study enrolled women with locally advanced or metastatic breast cancer in an earlier line of treatment ...
Hatfield, England (ots/PRNewswire) - Zonegran(R) (zonisamide) set to offer new option for epilepsy treatment in Russia Eisai, one of the world's leading research-based pharmaceutical companies, announces the expansion of its operations into Russia, with the approval of its first product - the epilepsy treatment, Zonegran(R) (zonisamide). Eisai's entry into the Russian healthcare marketplace is part of the company's plan ...
Hatfield, England (ots/PRNewswire) - ? Reimbursement granted for Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited today announces the launch of Zebinix(R) (eslicarbazepine acetate) which will receive full reimbursement from the Swedish health authorities. Once-daily Zebinix is indicated as an adjunctive (add-on) therapy for adults with partial-onset ...
Hatfield, England (ots/PRNewswire) - Eisai announced today that 12 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, USA, from 1-5 June 2012. These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's ...
Frankfurt And Hatfield, England (ots/PRNewswire) - ? The German Federal Joint Committee (G-BA), the supreme decision-making body of the self-governing medical system in Germany, announced that it considers the use of Halaven(R) (eribulin) to have additional benefit versus comparative treatments, defined by the G-BA ...
Hatfield, England (ots/PRNewswire) - Reimbursement granted for Zebinix(R) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited announces the launch of Zebinix(R) (eslicarbazepine acetate) in France. Upon launch, this novel epilepsy drug will receive full reimbursements from the French health authorities. Once-daily eslicarbazepine acetate is indicated as an adjunctive (add-on) therapy for ...
Hatfield, England (ots/PRNewswire) - New EMEA Dubai Office Part of Expansion Plans into Middle East and Parts of Africa PRESS RELEASE NOT INTENDED FOR DUBAI MEDIA Japanese company Eisai is expanding its geographical and patient reach by opening a new regional representative office in Dubai today. The Eisai EMEA (Europe, Middle East and Africa) Dubai branch office, located in Dubai Healthcare City (DHCC), marks the ...
Hatfield, England (ots/PRNewswire) - Child-friendly formulation now available for the treatment of Lennox-Gastaut syndrome Eisai Europe Limited today announced the launch of Inovelon(R) (rufinamide) oral suspension in Denmark for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS), in children four years and older. Many patients who receive the orphan drug rufinamide are children, ...